Sachiyo Minegishi
About Sachiyo Minegishi
Sachiyo Minegishi, MBA, 47, is an independent director of Mural Oncology plc and has served on the board since September 2024. She is Chief Operating Officer of Rectify Pharmaceutical, Inc. (private) and previously served as CFO of Akouos, Inc., where she helped lead the company’s acquisition by Eli Lilly; earlier roles include VP, Global Program Lead at bluebird bio and leadership positions at Aegerion, Human Genome Sciences, Genzyme, and Amgen; she holds a B.S. in Chemical Engineering and Economics from MIT and an MBA from Wharton . The board has determined she is independent under Nasdaq rules; she chairs the Audit Committee and serves on the Nominating & Corporate Governance Committee; all directors met at least 75% attendance in 2024 board and committee meetings .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Rectify Pharmaceutical, Inc. (private) | Chief Operating Officer | Apr 2023 – Present | Senior operating leadership |
| Akouos, Inc. | Chief Financial Officer | Oct 2020 – Feb 2023 | Helped lead acquisition by Eli Lilly |
| bluebird bio, Inc. | VP, Global Program Lead | Apr 2016 – Sep 2020 | Program leadership |
External Roles
| Organization | Role | Public/Private | Notes |
|---|---|---|---|
| Rectify Pharmaceutical, Inc. | Chief Operating Officer | Private | Current operating role alongside Mural directorship |
No other public-company directorships are disclosed for Ms. Minegishi in Mural’s proxy biography .
Board Governance
- Independence: The board determined all directors other than the CEO are independent under Nasdaq and Exchange Act criteria; this includes Ms. Minegishi .
- Committee assignments:
- Audit Committee: Chair; designated “audit committee financial expert”; the committee met 4 times in 2024 .
- Nominating & Corporate Governance Committee: Member; the committee met 2 times in 2024 .
- Attendance and engagement: The board met 6 times in 2024; each director attended ≥75% of aggregate board and committee meetings; directors attended the 2024 AGM .
- Board leadership: Chair of the Board is Scott Jackson; CEO is separate (Caroline Loew) .
2025 Director Election Result (support signal)
| Nominee | For | Against | Abstain |
|---|---|---|---|
| Sachiyo Minegishi, MBA | 5,883,528 | 593,623 | 5,276 |
Fixed Compensation
Non-Employee Director Compensation Program (structure)
| Element | Member Annual Fee ($) | Chair Additional Annual Fee ($) |
|---|---|---|
| Board of Directors | 40,000 | 30,000 |
| Audit Committee | 7,500 | 7,500 |
| Compensation Committee | 6,000 | 6,000 |
| Nominating & Corporate Governance Committee | 5,000 | 5,000 |
- Fees are paid quarterly in arrears and prorated based on actual service days; reasonable travel expenses reimbursed .
2024 Director Compensation (Ms. Minegishi)
| Component | Amount ($) |
|---|---|
| Fees earned or paid in cash | 16,793 |
| Option awards (grant-date fair value) | 33,424 |
| Total | 50,217 |
Performance Compensation
Director Equity Program (structure)
| Equity Type | Grant Sizing | Vesting | Notes |
|---|---|---|---|
| Initial option (upon appointment) | 0.09% of shares outstanding on grant date | 12 equal quarterly installments over 3 years | 10-year term; exercise at FMV |
| Annual option (continuing directors) | 0.05% of shares outstanding on grant date | Vests in full by earlier of 1-year or next AGM | 10-year term; exercise at FMV |
Ms. Minegishi – 2024 Grant Details
| Grant | Shares | Vesting | Notes |
|---|---|---|---|
| Non-employee director option | 15,335 | 12 equal quarterly installments over 3 years | Granted in 2024 under 2023 Plan |
No performance share units (PSUs) or performance metrics are disclosed for non-employee directors; director options are time-based .
- Compensation Recovery (Clawback) Policy applies to Section 16 executive officers’ incentive compensation upon a restatement; not described as applicable to director equity .
- Anti-hedging: Directors are prohibited from short sales and derivative or hedging transactions in company securities .
Other Directorships & Interlocks
| Person | Other Public Boards (current) | Committee Roles Elsewhere | Interlocks/Customer-Supplier Relationships |
|---|---|---|---|
| Sachiyo Minegishi | None disclosed | Not disclosed | No related-party ties disclosed in proxy’s related-person transactions section for Ms. Minegishi – |
Expertise & Qualifications
- Financial expertise: Designated audit committee financial expert; possesses required financial sophistication under Nasdaq rules .
- Education: B.S. Chemical Engineering & Economics (MIT); MBA (Wharton) .
- Operating and finance experience: COO (Rectify); prior CFO (Akouos); program leadership (bluebird bio); prior roles at Aegerion, HGS, Genzyme, Amgen .
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| Beneficial ownership (shares) | 2,558 | As of Apr 4, 2025 record date |
| Ownership (%) | <1% | Based on 17,268,273 shares outstanding |
| Composition | Options exercisable within 60 days | Beneficial holdings for directors noted as options exercisable within 60 days |
| Options outstanding (context) | 15,335 | Option award held as of Dec 31, 2024 (not all exercisable by record date) |
| Hedging/Pledging | Hedging prohibited by policy; no pledges disclosed for Ms. Minegishi | Anti-hedging policy applies to directors ; no pledge disclosure in beneficial table |
Governance Assessment
- Strengths: Independent director with deep operating and finance background; Audit Chair and audit committee financial expert provide strong oversight of reporting, controls, and enterprise risk (including cybersecurity) . Solid shareholder support in 2025 director election (5.88M For vs. 0.59M Against) signals investor confidence in board composition .
- Alignment/Pay: Director pay mix includes equity via options that vest over time, aligning service with shareholder outcomes; cash retains are modest and role-appropriate, with incremental fees for Audit Chair responsibilities .
- Conflicts/Red flags: Related-person transactions disclosed relate to the Alkermes separation; no transactions involving Ms. Minegishi are identified; the Audit Committee oversees related-party reviews – . Directors are subject to an anti-hedging policy; the company has an executive-officer clawback policy; no option repricings or attendance concerns disclosed .